Saltar al contenido
Merck
  • Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.

Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.

Journal of medicinal chemistry (2012-10-19)
Cullen L Cavallaro, Stephanie Briceno, Jing Chen, Mary Ellen Cvijic, Paul Davies, John Hynes, Rui-Qin Liu, Sandhya Mandlekar, Anne V Rose, Andrew J Tebben, Katy Van Kirk, Andrew Watson, Hong Wu, Guchen Yang, Percy H Carter
RESUMEN

A series of novel, potent CCR1 inhibitors was developed from a moderately active hit using an iterative parallel synthesis approach. The initial hit (composed of three subunits: an amine, a central amino acid, and an N-terminal cap) became the basis for a series of parallel chemical libraries designed to generate SAR data. Libraries were synthesized that explored each of the three subunits; the CCR1 binding data obtained revealed the following: (1) changes to the amine are not well tolerated; (2) small alkylamino acids are preferred in the center of the molecule; (3) substitutions at the N-terminus are generally well tolerated. These data were used to drive the optimization of the series, ultimately providing a lead with a CCR1 binding IC(50) of 28 nM (48). This lead demonstrates high selectivity for CCR1 over other CCR-family members, high microsomal stability, and good pharmacokinetics in mice.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Piperidine, ReagentPlus®, 99%
Sigma-Aldrich
Piperidine, ≥99.5%, purified by redistillation
Sigma-Aldrich
Piperidine, biotech. grade, ≥99.5%
Sigma-Aldrich
Piperidine solution, suitable for peptide synthesis, 20% in DMF